Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 13, 2026

Altus Group Announces Completion of Substantial Issuer Bid

View original at globenewswire.com
Altus Group Announces Completion of Substantial Issuer Bid TORONTO, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Altus Group has a global team of approximately 1,800 experts

    80% confidence
  • Shareholders who sold shares under the SIB will be deemed to have received a taxable dividend equal to the amount by which the purchase price exceeds the paid-up capital per share

    80% confidence
  • The dividend deemed to have been paid is designated as an 'eligible dividend' for Canadian tax purposes

    80% confidence
  • The specified amount for purposes of subsection 191(4) of the Income Tax Act (Canada) is C$55.75, being the closing trading price for the shares on the TSX on January 8, 2026

    80% confidence
  • The paid-up capital per share is approximately C$17.84 for purposes of the Income Tax Act (Canada)

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com